Zeus Scientific has received emergency use authorization (EUA) for additional automation claims from the FDA for its in vitro ELISA diagnostic test for the qualitative detection of IgG antibodies to the SARS-CoV-2 (Novel 2019) coronavirus in human serum and plasma. The Zeus ELISA SARS-CoV-2 IgG Test System is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The assay utilizes a dual antigen combination of recombinant S1 receptor binding domain (RBD) viral protein and recombinant nucleoprotein that detects immune responses that other antibody tests may miss.

The SARS-CoV-2 IgG Test System was first granted EUA in October of 2020 to run manually or using the Dynex Agility Automated ELISA System. The FDA has extended this EUA to now include the Dynex DS2 and Dynex DSX instruments.  Combined with the recent additional FDA EUA Zeus ELISA SARS-CoV-2 Total Antibody Test System, Zeus now provides a comprehensive portfolio of FDA EUA ELISA SARS-CoV-2 antibody tests, which includes validated full automation on the Dynex Technologies suite of instruments (DS2, DSX, Agility). 

According to the company, the Dynex Agility offers the highest throughput and takes advantage of the SmartKit Gold packaging, providing the ability to fully automate the procedure from sample to result with a throughput meeting all laboratory requirements. Both assays follow Zeus’s universal ELISA assay protocol. This protocol offers a high degree of flexibility with incubation times allowing for simple, efficient, and flexible automation programming on open pipetting systems.     

For more information, visit Zeus Scientific